• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

α1-酸性糖蛋白与丙吡胺及单-N-去烷基丙吡胺在全血中的分布关系

Relationship between alpha 1-acid glycoprotein and distribution of disopyramide and mono-N-dealkyldisopyramide in whole blood.

作者信息

Bredesen J E, Kierulf P

出版信息

Br J Clin Pharmacol. 1986 Sep;22(3):281-6. doi: 10.1111/j.1365-2125.1986.tb02888.x.

DOI:10.1111/j.1365-2125.1986.tb02888.x
PMID:3768240
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1401135/
Abstract

The binding of disopyramide (DP) and mono-N-dealkyldisopyramide (MND) was measured by equilibrium dialysis in spiked whole blood (10 mumol l-1 DP or MND) from 50 patients having a serum concentration of alpha 1-acid glycoprotein (AAG) ranging from 0.40 to 3.14 g l-1, as well as in whole blood from five healthy subjects, spiked with different concentrations of AAG ranging from 0.61 to 3.33 g l-1. The binding ratio (moles bound divided by moles unbound) in all samples increased from 1.0 to 8.0 for DP and 0.6 to 3.3 for MND with increasing AAG concentrations. The binding varied according to the AAG concentrations both in patients and healthy subjects. Similarly total and free plasma concentrations of DP and MND were also measured. With increasing AAG concentrations the total concentrations measured increased from 9.0 to 15.9 mumol l-1 for DP and from 6.8 to 11.8 mumol l-1 for MND whereas the free concentrations decreased from 3.8 to 0.5 mumol l-1 for DP and from 5.0 to 2.0 mumol l-1 for MND. With increasing AAG concentrations the whole blood/plasma concentration ratio decreased from 1.11 and 1.47 to 0.63 and 0.85 for DP and MND respectively. The ratio between their concentration in cells and the unbound concentration in plasma, however, was constant over the whole AAG concentration range. The mean ratios for all samples were 3.0 and 3.1 for DP and MND respectively, indicating that both compounds are bound or distributed to the blood cells. The distribution of the drugs in whole blood changed according to increasing AAG concentrations.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

通过平衡透析法测定了50例血清α1 -酸性糖蛋白(AAG)浓度范围为0.40至3.14 g/l的患者以及5名健康受试者的加标全血(10 μmol/l双异丙吡胺或单N -去烷基双异丙吡胺)中双异丙吡胺(DP)和单N -去烷基双异丙吡胺(MND)的结合情况。这5名健康受试者的全血中加入了浓度范围为0.61至3.33 g/l的不同浓度AAG。随着AAG浓度增加,所有样本中DP的结合率(结合摩尔数除以未结合摩尔数)从1.0增至8.0,MND的结合率从0.6增至3.3。患者和健康受试者的结合情况均随AAG浓度而变化。同样地,还测定了DP和MND的血浆总浓度和游离浓度。随着AAG浓度增加,测定的DP总浓度从9.0增至15.9 μmol/l,MND从6.8增至11.8 μmol/l,而DP的游离浓度从3.8降至0.5 μmol/l,MND从5.0降至2.0 μmol/l。随着AAG浓度增加,DP和MND的全血/血浆浓度比分别从1.11和1.47降至0.63和0.85。然而,它们在细胞中的浓度与血浆中未结合浓度的比值在整个AAG浓度范围内保持恒定。所有样本中DP和MND的平均比值分别为3.0和3.1,表明这两种化合物均与血细胞结合或分布于血细胞中。全血中药物的分布随AAG浓度增加而变化。(摘要截短至250字)

相似文献

1
Relationship between alpha 1-acid glycoprotein and distribution of disopyramide and mono-N-dealkyldisopyramide in whole blood.α1-酸性糖蛋白与丙吡胺及单-N-去烷基丙吡胺在全血中的分布关系
Br J Clin Pharmacol. 1986 Sep;22(3):281-6. doi: 10.1111/j.1365-2125.1986.tb02888.x.
2
Relationship between alpha 1-acid glycoprotein and plasma binding of disopyramide and mono-N-dealkyldisopyramide.α1-酸性糖蛋白与丙吡胺及单-N-去烷基丙吡胺血浆结合之间的关系
Br J Clin Pharmacol. 1984 Nov;18(5):779-84. doi: 10.1111/j.1365-2125.1984.tb02542.x.
3
Plasma binding of disopyramide and mono-N-dealkyldisopyramide.丙吡胺及单-N-去烷基丙吡胺的血浆结合情况。
Br J Clin Pharmacol. 1982 Nov;14(5):673-6. doi: 10.1111/j.1365-2125.1982.tb04955.x.
4
A simple method for the simulation of unbound serum disopyramide concentration in patients.
J Pharmacobiodyn. 1991 Sep;14(9):493-9. doi: 10.1248/bpb1978.14.493.
5
[Accumulation of a disopyramide metabolite in renal failure].[肾功能衰竭时丙吡胺代谢产物的蓄积]
Nihon Jinzo Gakkai Shi. 1993 Sep;35(9):1065-71.
6
Effects of serum concentrations of disopyramide and its metabolite mono-N-dealkyldisopyramide on the anticholinergic side effects associated with disopyramide.丙吡胺及其代谢产物单 -N-去烷基丙吡胺的血清浓度对丙吡胺相关抗胆碱能副作用的影响。
Biol Pharm Bull. 2008 Jul;31(7):1368-70. doi: 10.1248/bpb.31.1368.
7
Protein binding of disopyramide--displacement by mono-N-dealkyldisopyramide and variation with source of alpha-1-acid glycoprotein.丙吡胺的蛋白结合——单-N-去烷基丙吡胺的置换作用及与α-1-酸性糖蛋白来源的关系
J Pharm Pharmacol. 1985 Apr;37(4):285-8. doi: 10.1111/j.2042-7158.1985.tb05066.x.
8
Accumulation of a disopyramide metabolite in renal failure.
ASAIO J. 1993 Jul-Sep;39(3):M609-13.
9
Changes in the binding capacity of alpha-1-acid glycoprotein in patients with renal insufficiency.肾功能不全患者α1-酸性糖蛋白结合能力的变化。
Ther Drug Monit. 1995 Oct;17(5):449-53. doi: 10.1097/00007691-199510000-00003.
10
Simultaneous determination of disopyramide and its mono-N-dealkylated metabolite enantiomers in human plasma and urine by enantioselective high-performance liquid chromatography.
J Chromatogr. 1990 Aug 3;529(2):347-58. doi: 10.1016/s0378-4347(00)83841-4.

引用本文的文献

1
Disopyramide. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias.丙吡胺。对其药效学和药代动力学特性以及在心律失常治疗中的应用的重新评估。
Drugs. 1987 Aug;34(2):151-87. doi: 10.2165/00003495-198734020-00001.
2
Effects of cardiovascular disease on pharmacokinetics.心血管疾病对药代动力学的影响。
Cardiovasc Drugs Ther. 1989 Oct;3(5):711-30. doi: 10.1007/BF01857622.

本文引用的文献

1
Plasma binding of disopyramide.丙吡胺的血浆结合
Br J Clin Pharmacol. 1980 Jun;9(6):614-8. doi: 10.1111/j.1365-2125.1980.tb01090.x.
2
Concentration-dependence of disopyramide binding to plasma protein and its influence on kinetics and dynamics.丙吡胺与血浆蛋白结合的浓度依赖性及其对动力学和动力学的影响。
J Pharmacol Exp Ther. 1981 Dec;219(3):741-7.
3
Gas-chromatographic determination of disopyramide and its mono-N-dealkylated metabolite in serum with use of a nitrogen-selective detector.使用氮选择性检测器通过气相色谱法测定血清中的丙吡胺及其单-N-脱烷基代谢物。
Clin Chem. 1980 Apr;26(5):638-40.
4
Plasma concentrations and protein binding of disopyramide and mono-N-dealkyldisopyramide during chronic oral disopyramide therapy.慢性口服丙吡胺治疗期间丙吡胺及单-N-去烷基丙吡胺的血浆浓度和蛋白结合率
Br J Clin Pharmacol. 1981 Apr;11(4):369-75. doi: 10.1111/j.1365-2125.1981.tb01134.x.
5
Plasma binding of disopyramide and mono-N-dealkyldisopyramide.丙吡胺及单-N-去烷基丙吡胺的血浆结合情况。
Br J Clin Pharmacol. 1982 Nov;14(5):673-6. doi: 10.1111/j.1365-2125.1982.tb04955.x.
6
Pharmacology of commonly used antiarrhythmic drugs and comments on the use of therapeutic drug monitoring.
Ther Drug Monit. 1982;4(1):1-14. doi: 10.1097/00007691-198204000-00001.
7
Prolonged variability in plasma protein binding of disopyramide after acute myocardial infarction.急性心肌梗死后丙吡胺血浆蛋白结合的长期变异性。
Br J Clin Pharmacol. 1983 Apr;15(4):435-41. doi: 10.1111/j.1365-2125.1983.tb01527.x.
8
Effect of heparin on the red blood cell-to-plasma concentration ratio of diphenylhydantoin and prazosin.
Ther Drug Monit. 1983;5(4):497-9. doi: 10.1097/00007691-198312000-00019.
9
Drug binding in sera deficient in lipoproteins, albumin or orosomucoid.在缺乏脂蛋白、白蛋白或类粘蛋白的血清中的药物结合。
Br J Clin Pharmacol. 1983 Sep;16(3):233-9. doi: 10.1111/j.1365-2125.1983.tb02155.x.
10
Determination of (R)- and (S)-disopyramide in human plasma using a chiral alpha 1-acid glycoprotein column.使用手性α1-酸性糖蛋白柱测定人血浆中的(R)-和(S)-丙吡胺。
J Chromatogr. 1984 Dec 12;336(2):321-8. doi: 10.1016/s0378-4347(00)85155-5.